[1]崔晶晶,庄伟,冯英楠,等.抗瘤丸结合西医常规疗法治疗恶性神经胶质瘤临床研究[J].国际中医中药杂志,2022,44(06):616-620.[doi:10.3760/cma.j.cn115398-20210916-00231]
　Cui Jingjing,Zhuang Wei,Feng Yingnan,et al.Clinical study on Kangliu Pill combined with conventional therapy in the treatment of malignant gliomas[J].,2022,44(06):616-620.[doi:10.3760/cma.j.cn115398-20210916-00231]
点击复制

抗瘤丸结合西医常规疗法治疗恶性神经胶质瘤临床研究

《国际中医中药杂志》[ISSN:1673-4246/CN:CN11-5398/R] 卷: 44 期数: 2022年第06期 页码: 616-620 栏目: 临床研究 出版日期: 2022-06-17
Title:
Clinical study on Kangliu Pill combined with conventional therapy in the treatment of malignant gliomas
作者:
崔晶晶1; 庄伟1; 冯英楠1; 孙格1; 林庆堂2; 吴晓光3; 林晓兰1
1首都医科大学宣武医院药学部 国家老年疾病临床医学研究中心,北京 100053 ;2首都医科大学宣武医院神经外科,北京 100053 ;3首都医科大学宣武医院流行病学与社会医学部,北京 100053
Author(s):
Cui Jingjing1;  Zhuang Wei1;  Feng Yingnan1;  Sun Ge1;  Lin Qingtang2;  Wu Xiaoguang3;  Lin Xiaolan1
1 Department of Pharmacy, Xuanwu Hospital of Capital Medical University, National Gerontic Disease Clinical Research Center, Beijing 100053, China; 2 Department of Neurosurgery, Xuanwu Hospital of Capital Medical University, Beijing 100053, China; 3 Department of Epidemiology and Social Medicine, Xuanwu Hospital of Capital Medical University, Beijing 100053, China
关键词:
神经胶质瘤;  抗瘤丸;  中西医结合疗法;  生存状况
DOI:
10.3760/cma.j.cn115398-20210916-00231
摘要:
目的　评价抗瘤 丸结合西医常规疗法治疗恶性神经胶质瘤术后患者的疗效。方法　将符合入选标准的 2017年1月－2019年11月行恶性神经胶质瘤（Ⅲ～Ⅳ级）手术切除患者100例，按治疗方法分为治疗组48例、对照组52例，对照组采用常规手术加放化疗治疗，治疗组在对照组基础上加服抗瘤丸。随访1～2年，记录患者生存率、无进展生存期、中位生存期，采用Karnofsky功能状态评分（KPS）、生活质量评分（QOL）评价患者生存及生活质量，观察治疗期间的不良反应。结果　治疗组 1年、2年生存率［97.92%（47/48）、68.75%（33/48）］高于对照组［80.77%（42/52）、42.31%（22/52）］（χ2值分别5.847、7.051，P值分别为0.016、0.008）；治疗组无进展生存期［（23.94±13.12）个月比（15.82±8.65）个月，t=3.63］高于对照组（P<0.01）；采用寿命表法进行生存分析，得到治疗组中位生存期为21.13个月，对照组中位生存期为12.00个月，2组中位生存期、累计生存率比较差异均具有统计学意义（P=0.001）；治疗组KPS、QOL评分均高于对照组，但组间比较差异均无统计学意义（P>0.05）。2组治疗期间均未发生严重不良反应。结论　抗瘤丸辅助治疗可提高恶性神经胶质瘤术后患者生存率，延长无进展生存期、中位生存期，改善生活质量，提高疗效，且安全性较好。

参考文献/References:

[1] Ghotme KA,Barreto GE,Echeverria V,et al. Gliomas: New Perspectives in Diagnosis,Treatment and Prognosis[J]. Curr Top Med Chem ,2017,17(12):1438-1447. DOI:10.2174/1568026617666170103162639.

[2] Chen J,McKay RM,Parada LF. Malignant glioma :lessons from geno mics,mouse models,and stem cells[J]. Cell,2012,149(1):36-47. DOI:10.1016/j.cell.2012.03.009.

[3] Stupp R,Tonn JC,Brada M,et al. High-grade malignant glioma:ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up[J]. Ann Oncol ,2010,21(Suppl 5):v190-v193. DOI:10.1093/annonc/mdq187.

[4] Wang Y,Zhang Q,Chen Y,et al. Antitumor effects of immunity-enhancing traditional Chinese medicine[J]. Biomed Pharmacother ,2020,121:109570. DOI:10.1016/j.biopha.2019.109570.

[5] 庄伟,林晓兰,姜德春,等. 中药KLW-1治疗恶性神经胶质瘤的临床研究[J]. 中国新药杂志,2011,20(19):1894-1897.

[6] 王忆勤. 中医诊断学[M]. 北京:科学出版社,2007.

[7] 周良辅,毛颖,王任直. 中国中枢神经系统胶质瘤诊断与治疗指南(2015)[J]. 中华医学杂志,2016,96(7):485-509. DOI:10.3760/cma.j.issn.0376-2491.2016.07.003.

[8] Schag CC,Heinrich RL,Ganz PA. Karnofsky performa nce status revisited:reliability, validity, and guidelines[J]. J Clin Oncol,1984,2(3):187-193. DOI:10.1200/JCO.1984.2.3.187.

[9] Jocham HR,Dassen T,Widdershoven G,et al. Quality of life in palliative care cancer patients:a literature review[J]. J Clin Nur s,2006,15(9):1188-1195. DOI:10.1111/j.1365-2702.2006.01274.x.

[10] Kohler BA,Ward E,McCarthy BJ,et al. Annual report to the nation on the status of cancer,1975-2007,featuring tumors of the brain and other nervous system[J]. J Natl Cancer Inst,2011,103(9):714-736. DOI:10.1093/jnci/djr077.

[11] Crocetti E,Trama A,Stiller C,et al. Epidemiology of glial and non-glial brain tumours in Europe[J]. Eur J Cancer,2012,48(10):1532-1542. DOI:10.1016/j.ejca.2011.12.013.

[12] Digregorio M,Lombard A,Lumapat PN,et al. R elevance of Translation Initiation in Diffuse Glioma Biology and its Therapeutic Potential[J]. Cells,2019,8(12):1542. DOI:10.3390/cells8121542.

[13] Reni M,Mazza E,Zanon S,et al. Central nervous system gliomas[J]. Crit Rev Oncol Hematol,2017,113:213-234. DOI:10.1016/j.critrevonc.2017.03.021.

[14] 刘涌涛,石志超. 中医药治疗脑胶质瘤的经验总结[J]. 中国民康医学,2019,31(19):136-137. DOI:10.3969/j.issn.1672-0369.2019.19.060.

[15] 梁冰. 周仲瑛教授病机辨治原发性颅内肿瘤临床经验与学术思想研究[D]. 南京:南京中医药大学,2016.

[16] Wang T,Guo R,Zhou G,et al. Traditional uses, botany, phytochemistry, pharmacology and toxicology of Panax notoginseng (Burk.) F.H. Chen:A review[J]. J Ethnopharmacol ,2016,188:234-258. DOI:10.1016/j.jep.2016.05.005.

[17] Wang L,Chen W,Li M,et al. A review of the ethnopharmacology, phytochemistry, pharmac ology, and quality control of Scutellaria barbata D. Don[J]. J Ethnopharmacol,2020,254:112260. DOI:10.1016/j.jep.2019.112260.

[18] Wang C,Zhou X,Wang Y,et al. The Antitumor Constituents from Hedyotis Diffusa Willd[J]. Molecules,2017,22(12):2101. DOI:10.3390/molecules22122101.

[19] Chen T,Zhong F,Yao C,et al. A Systematic Review on Traditional Uses ,Sources,Phytochemistry,Pharmacology, Pharmacokinetics,and Toxicity of Fritillariae Cirrhosae Bulbus[J]. Evid Based Complement Alternat Med,2020,2020:1536534. DOI:10.1155/2020/1536534.

[20] Lin L,Ni B,Lin H,et al. Traditional usages, botany,phytochemistry,pharmacology and toxicology of Polygonum multiflorum Thunb.:a review[J]. J Ethnopharmacol,2015,159:158-183. DOI:10.1016/j.jep.2014.11.009.

[21] 胡梦梅. 土茯苓化学成分分离及抗炎活性研究[D]. 广州:广州中医药大学,2014.

[22] 张鹏,冯英楠,王海征,等. 中药复方抗瘤丸治疗神经胶质瘤作用机制的实验研究[J]. 北京中医药,2017,36(2):135-138,193. DOI:10.16025/j.1674-1307.2017.02.012.

[23] 冯英楠,张鹏,陈菲,等. 中药复方抗瘤丸优化方对U87裸鼠移植瘤动物模型作用机制研究[J]. 环球中医药,2018,11(10):1515-1519. DOI:10.3969/j.issn.1674-1749. 2018.10.004.

[24] Sun G,Zhuang W,Lin QT,et al. Partial response to Chinese patent medicine Kangliu pill for adult glioblastoma:A case report and review of the literature[J]. World J Clin Cases,2021,9(12):2845-2853. DOI:10.12998/wjcc.v9.i12.2845.

备注/Memo

基金项目：北京市科委“十病十药”专项（Z171100001717006）；北京市中医药科技项目（JJ-2016-10）；国家中医药管理局全国中医药创新骨干人才培训项目（国中医药人教函〔2019〕128号）

更新日期/Last Update:

2022-06-17